Search clinical trials for: olaparib,itraconazole,

Total 827 results

West China Hospital

Terminated

Treatment Method Research of Invasive Pulmonary Fungal Infection (4056)

IFI

China
University Health Network, Toronto
AstraZeneca

Completed

A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib

Ovarian Cancer

Canada
Reata, a wholly owned subsidiary of Biogen

Completed

Effect of Itraconazole on the Pharmacokinetics of Bardoxolone Methyl in Healthy Adults

Healthy Volunteers

United States
Pfizer

Completed

Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single-Dose of PF-06651600 in Healthy Participants

Healthy Participants

Belgium
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer

Pancreatic Cancer

United States
Rush University Medical Center

Active, not recruiting

A Study of Serum Folate Levels in Patients Treated With Olaparib

Breast Cancer | Ovarian Cancer | Folic Acid Deficiency

United States
Dhaka Medical College

Not yet recruiting

Efficacy and Safety of Terbinafine and Itraconazole

Tinea Cruris | Tinea Corporis | Dermatophytoses | Tinea Faciei
Seoul National University Hospital

Completed

Pharmacokinetics of Itraconazole in Pediatric Cancer Patients

Pediatric, Cancer

Korea, Republic of
Beth Israel Deaconess Medical Center
Johns Hopkins University; Dana-Farber Cancer Institute; AstraZeneca

Active, not recruiting

Olaparib In Metastatic Breast Cancer

Metastatic Breast Cancer | Invasive Breast Cancer | BRIP1 Gene Mutation | PALB2 Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | Somatic Mutation Breast Cancer (BRCA1) | Somatic Mutation Breast Cancer (BRCA2)

United States
AstraZeneca

Completed

AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors

Refractory Solid Tumours | Relapsed Small Cell Lung Cancer (SCLC)

United States, Canada
AstraZeneca

No longer available

Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan

PSR Ovarian Cancer With a BRCA Mutation

Japan
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.

Completed

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments (SOLO3)

Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity

United States, Italy, Spain, Belgium, Poland, Canada, Korea, Republic of, Brazil, Czechia, Hungary, Israel, Argentina, Mexico
Avanir Pharmaceuticals

Completed

Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts (DDI)

Healthy

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics (PK) of Nemiralisib

Pulmonary Disease, Chronic Obstructive

United States
AstraZeneca

Completed

A Phase I Study to Assess PK of AZD7986 Alone & With Verapamil, Itraconazole or Diltiazem in Healthy Subjects

Healthy Subjects

United Kingdom
University of Utah
Repare Therapeutics

Recruiting

RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia (CORONADO CLL)

Chronic Lymphocytic Leukemia

United States
AstraZeneca

Completed

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

Ovarian Cancer

Canada, Czechia, Poland, Romania, United States, Belgium, France, Russian Federation, United Kingdom, Israel, Spain, Germany, Austria, Netherlands, Australia, Estonia, Ukraine
Tianjin Medical University Cancer Institute and...

Recruiting

Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer

Extensive-stage Small Cell Lung Cancer

China
Erasmus Medical Center

Recruiting

Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors (PRRT-PARPi)

Neuroendocrine Tumors | Peptide Receptor Radionuclide Therapy

Netherlands
AstraZeneca

Completed

Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies

Cancer | Advanced Solid Malignancies

Japan
Ain Shams University

Unknown

Itraconazole in Non Small Cell Lung Cancer

Lung Cancer

Egypt
Astellas Pharma Europe B.V.
Medivation, Inc.

Completed

Drug-drug Interaction Study With MDV3100 (ASP9785) and Gemfibrozil and Itraconazole

Healthy Subjects | Pharmacokinetics | Drug-Drug Interaction

France
Janssen Pharmaceuticals

Completed

Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis.

HIV Infections | Candidiasis, Esophageal

United States
AstraZeneca

Completed

Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status

Colorectal Cancer

United States
National Cancer Institute, Naples

Recruiting

Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study (MITO 31)

BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

Italy
National Cancer Institute (NCI)

Recruiting

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

Lung Neoplasms | Small Cell Lung Cancer | Prostate Cancer | Urothelial Carcinoma | Urothelial Cancer

United States
AstraZeneca
Parexel

Approved for marketing

Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Ovarian Cancer

United States
Se-Hoon Lee
Roche Pharma AG; AstraZeneca

Completed

Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects (SUKSES-B2)

Lung Cancer

Korea, Republic of
The Netherlands Cancer Institute

Completed

Olaparib and Radiotherapy in Inoperable Breast Cancer

Locally Advanced Malignant Neoplasm | Triple-Negative Invasive Breast Carcinoma | Inflammatory Breast Carcinoma

Netherlands
Dana-Farber Cancer Institute
AstraZeneca; Osteosarcoma Institute

Recruiting

Olaparib With Ceralasertib in Recurrent Osteosarcoma

Osteosarcoma | Osteosarcoma Recurrent

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
AstraZeneca; The Marcus Foundation; McGuff Pharmaceuticals, Inc.

Recruiting

Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer

Prostate Cancer | Castration-resistant Prostate Cancer

United States
Alexander B Olawaiye, MD
AstraZeneca

Recruiting

Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency

Ovarian Cancer

United States
Azienda Ospedaliero-Universitaria di Modena

Recruiting

Olaparib in PALB2 Advanced Pancreatic Cancer (PALBOLA)

Metastatic Pancreatic Cancer | Advanced Pancreatic Cancer

Italy
Anthony Joshua, FRACP
St Vincent's Hospital, Sydney; Royal Prince Alfred Hospital, Sydney, Australia and other collaborators

Recruiting

Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer (TICTOC)

Ovarian Cancer

Australia
The Netherlands Cancer Institute
AstraZeneca

Active, not recruiting

Olaparib and Radiotherapy in Head and Neck Cancer

Head and Neck Neoplasms | Carcinoma, Squamous Cell | Laryngeal Cancer Stage II | Laryngeal Cancer Stage III

Netherlands
AstraZeneca

Active, not recruiting

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

Breast | Prostate | Ovarian | Pancreatic | Advanced Tumours

Sweden, Spain, Israel, Australia, Germany
Dizal Pharmaceuticals

Recruiting

Drug-drug Interactions Between AZD4205 and Itraconazole/Carbamazepine

Healthy Subjects

United States
Poitiers University Hospital

Recruiting

Chronic Pulmonary Aspergillosis and Ambisome Aerosol With Itraconazole

Chronic Pulmonary Aspergillosis

France
AstraZeneca
Parexel

Recruiting

Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).

Opioid Use Disorder

United States
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP3700 in Healthy Male Subjects

Healthy Volunteers | Pharmacokinetics of ASP3700

United Kingdom
Brown University
AstraZeneca; The Miriam Hospital; Rhode Island Hospital

Terminated

BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects in DNA Repair Genes (337)

Prostate Cancer | Adenocarcinoma of the Prostate

United States
Royal Marsden NHS Foundation Trust
AstraZeneca; Institute of Cancer Research, United Kingdom

Completed

Trial of Olaparib in Combination With AZD5363 (ComPAKT) (ComPAKT)

Advanced Cancer

United Kingdom
Dizal Pharmaceuticals

Completed

Drug-drug Interactions Between DZD9008 and Itraconazole/Carbamazepine

Healthy Subjects

United States
University of Texas Southwestern Medical Center
United States Department of Defense

Completed

Neoadjuvant Itraconazole in Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
Fujian Medical University

Unknown

Posaconazole vs Itraconazole in Preventing IFD Post-HSCT

IFD Post-HSCT

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Effect of Itraconazole on the Pharmacokinetics of Apatinib

Neoplasms

China
Biogen

Completed

Effect of Itraconazole on the Pharmacokinetics of BIIB074

Neuropathic Pain

United Kingdom
Pfizer

Completed

Effect Of Itraconazole On The Pharmacokinetics Of Palbociclib

Healthy

United States
Italian Sarcoma Group
AstraZeneca; PharmaMar

Active, not recruiting

Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments. (TOMAS2)

Advanced Soft Tissue Sarcoma

Italy
AstraZeneca

Active, not recruiting

Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer (OlympiaN)

Breast Cancer

United States, Belgium, Italy, Spain, United Kingdom, Germany, Austria, Israel, Australia

Search clinical trials for: olaparib,itraconazole,

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations